Search for drugs:
Typing the drug name to query
SELEXIPAG
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac electrophysiology
- At the maximum tolerated dose of 1600 mcg twice daily, selexipag does not prolong the QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
4
24088
Other ADRs
50204
38331383
Odds Ratio = 0.127
Drug Property Information
ATC Code(s):
- B01AC27 - selexipag
- B01AC - Platelet aggregation inhibitors excl. heparin
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:SELEXIPAG
Active Ingredient UNII:5EXC0E384L
Drugbank ID:DB11362
PubChem Compound:9913767
CTD ID:C523468
CAS Number:475086-01-2
Dosage Form(s):kit; tablet, coated
Route(s) Of Administrator:oral
Daily Dose:
- 1.8 mg/day B01AC27
Chemical Structure: 
SMILE Code:
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.